JPRN-jRCTs032230212
Recruiting
未知
A multicenter, prospective, single-arm, study on the usefulness of blood flow evaluation of anastomotic site using the SPY-QP software system in rectal cancer minimally invasive surgery.
Watanabe Jun0 sites400 target enrollmentJuly 10, 2023
ConditionsRectal cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Rectal cancer
- Sponsor
- Watanabe Jun
- Enrollment
- 400
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients who are histologically proven to be rectal cancer
- •2\. The lower edge of the tumor is within 12 cm from the anal verge
- •3\. Patients diagnosed with Stage 0\-3 in preoperative diagnostic imaging
- •4\. Patients who are scheduled for rectal resectionwith intestinal anastomosis (including ISR, taTME)
- •5\. Patients with General State Performance Status(ECOG) 0 to 2
- •6\. Patients whose age at registration is 20 years or older
- •7\. Patients whose functions of the main organs are adequately maintained and judged to be safe for surgery by the doctor in charge of examination within 28 days prior to the surgery.
- •8\. About participation in this study Patients who have obtained consent from a document stating signature and date by the applicant
Exclusion Criteria
- •1\. Patients who are allergic to iodine orindocyanine green
- •2\. Planned surgery is rectal resection with combined resection of adjacent organ
- •3\. Preoperative intestinal obstruction patients
- •4\. Patients planning simultaneous resection of other organs due to double cancer
- •5\. Patients scheduled to anastomosis at more than two sites due to multiple colon cancer
- •6\. Patients with intraperitoneal infection (peritonitis or abdominal abscess)
- •7\. Patients with serious complications (heart disease, lung disease, bleeding tendency, poorly controlled hypertension, diabetes etc.)
- •8\. Concerning females, pregnancy and patients with fear thereof
- •9\. Other patients judged inappropriate by the examining physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A multi-center, single arm, prospective study of the WallFlex biliary partially covered stent for the palliative treatment of malignant bile duct obstruction.Malignant biliary obstructionmalignant obstruction of the biliary tract10019815NL-OMON30737Boston Scientific Corporation18
Completed
Not Applicable
OFT-G1-301 StudyCongenital heart diseaseJPRN-jRCT1080224691TEIJIN LIMITED / TEIJIN PHARMA LIMITED30
Completed
Not Applicable
A prospective, multi-center, single-arm study of tOCP/Col for guided bone regeneratiobone defectJPRN-UMIN000018192TOYOBO CO., LTD.60
Withdrawn
Phase 3
A Prospective, Multi-Center, Single Arm Study of the Conor Cobalt Chromium Reservoir Based Stent (Nevo) with Sirolimus Elution in Native Coronary Artery Lesions (CP-07 protocol)NL-OMON32462Conor Medsystems, LLC (maakt deel uit van Johnson & Johnson); contact persoon Emily Hergenreter40
Not yet recruiting
Phase 4
The aim is to evaluate the safety and efficacy of MeRes100™ Sirolimus Eluting BioResorbable Vascular Scaffold in coronary artery disease patients.It enhances coronary luminal diameter in symptomatic ischemic heart disease, addressing de novo lesions in native coronary arteries.Health Condition 1: I251- Atherosclerotic heart disease of native coronary arteryCTRI/2024/02/062438Meril Diagnostics Private Limited